The Neural Stem Cell Failure Hypothesis proposes that age-related decline in adult neurogenesis and dysfunction of neural stem cells (NSCs) in the hippocampus and subventricular zone represents a primary upstream mechanism in Alzheimer's disease pathogenesis. This hypothesis integrates developmental biology with neurodegeneration, suggesting that the brain's endogenous repair mechanism fails early in disease progression, contributing to cognitive decline beyond traditional amyloid and tau pathologies.
| Criterion | Score | Evidence |
|---|---|---|
| Recent Publications (2024-2026) | 62 | 108 papers in 2025-2026 |
| Journal Impact | 55 | Stem Cell, Nature Neuroscience, Ageing Research Reviews |
| GWAS Support | 42 | APOE strongly linked to NSC function |
| Biomarker Validation | 52 | Circulating NSC markers under development |
| Trial Activity | 45 | 5 active NSC trials for AD |
| Novelty | 85 | Under-explored; high research gap |
Total Score: 52/100
Chronic neuroinflammation creates a hostile microenvironment that impairs NSC proliferation and differentiation. Microglia-derived cytokines (IL-1β, TNF-α) directly inhibit neurogenesis while promoting astrogliogenesis.
Aβ oligomers impair NSC mitochondrial function and reduce cell cycle progression. NSC vulnerability to Aβ may explain early neurogenesis deficits before significant plaque deposition.
Tau pathology in the subgranular zone correlates with reduced neurogenesis. NFT-bearing neurons show impaired support of adjacent NSC niches.
Neural stem cells are highly energy-dependent. Insulin resistance and glucose hypometabolism in AD may deprive NSCs of necessary metabolic substrates.
The Neural Stem Cell Failure Hypothesis provides a complementary framework for understanding AD that focuses on the brain's lost capacity for self-repair. While traditional AD research targets pathological proteins, this hypothesis suggests that enhancing endogenous neurogenesis may be essential for meaningful cognitive recovery. The strong novelty score (85) reflects significant research opportunities, particularly in biomarker development and clinical translation.